Piper Sandler initiated coverage of Esperion (ESPR) with an Overweight rating and $9 price target
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ESPR:
- Esperion partner Otsuka launches NEXLETOL in Japan
- Esperion’s Global Expansion and Strategic Advancements Drive Buy Rating
- Esperion says HLS received approval from Health Canada to market NILEMDO
- Esperion’s Market Challenges: Sell Rating Due to Limited Impact of Bempedoic Acid and Mixed Feedback on Combination Strategy
- Esperion announces new data from CLEAR outcomes on NEXLETOL